Crinetics Pharmaceuticals, Inc. 4

Tobin Schilke, Chief Financial & Infrastructure Officer of Crinetics Pharmaceuticals, had all common shares, RSUs, and in-the-money stock options cashed out and canceled at the merger closing with Vertex Pharmaceuticals on September 1, 2026.

On September 1, 2026, in connection with the closing of Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals, Inc., Chief Financial & Infrastructure Officer Tobin Schilke’s equity holdings were cashed out and canceled in the merger. All 7,956 shares of common stock underlying previously outstanding RSUs, along with 71,471 directly held common shares, were converted into cash at the $85.00 per share merger price, resulting in an aggregate cash payout of approximately $6.78 million. In addition, vested in-the-money stock options to purchase 80,000 shares at an effective cash value of $51.25 per share (implied strike $33.75) and 50,000 shares at an effective cash value of $41.21 per share (implied strike $43.79) were canceled for cash, producing further consideration of about $4.10 million; following these transactions, Schilke reported no remaining equity ownership in Crinetics as it became a wholly owned subsidiary of Vertex.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059883

Alert Tier

6